Penn Medicine Abramson Cancer Center
2020 Updates in Oncology
Penn Medicine 2020 Updates in Oncology
Managing mNSCLC Patients With a Molecular Target: How Promising Are New RET & MET Inhibitors?
FEATURING
Joshua Bauml
- 132 views
- March 22, 2021
Penn Medicine 2020 Updates in Oncology
Myeloma Management Strategies: Efficacy Analysis of 1L Options & Anti-CD38 mAbs in R/R Disease
FEATURING
Dan T. Vogl
- 246 views
- January 27, 2021
- 1
Penn Medicine 2020 Updates in Oncology
COVID-19 Database Learnings and National Organization Responses: What Are the Current Clinical Guidelines for Cancer Patients? How Has Information Been Disseminated and Will We Be Able to Define Optimal Care in the Future?
FEATURING
Lawrence Shulman
- 33 views
- August 26, 2020
Penn Medicine 2020 Updates in Oncology
ASCO Update on Myeloma: How Promising Are BCMA CAR-T & BCMA x CD3 Bispecific T-Cell Therapies?
FEATURING
Dan T. Vogl
- 126 views
- July 22, 2020
- 1
Penn Medicine 2020 Updates in Oncology
2020 ASCO Update on RCC: IO + TKIs - Is There Long-term Efficacy?
FEATURING
Vivek Narayan
- 19 views
- July 15, 2020
Penn Medicine 2020 Updates in Oncology
2020 Update on MBC: Should Treatment of De Novo Disease Include Locoregional Therapy for the Primary? Does Pembro + Chemo Extend PFS in PD-L1 High-positive TNBC? Can Tucatinib Effectively Penetrate CNS in HER2+ Disease?
FEATURING
Angela DeMichele
- 188 views
- July 13, 2020
- 1
Penn Medicine 2020 Updates in Oncology
2020 Adjuvant Escalation and De-escalation in Early Stage BC: Is T-DM1/Pt Superior to THP for High-risk HER2+ Disease? 1 Year of Capecitabine vs. Observation in High-risk TNBC - Which Option Is Superior? Is There a Benefit to Anthracycline in HER2+ Disease?
FEATURING
Angela DeMichele
- 703 views
- July 13, 2020
- 3
Penn Medicine 2020 Updates in Oncology
2020 ASCO GI Cancer Update: Are CPIs Superior to 2nd Line Chemo in SSC of Esophagus? Is CROSS Regimen Beneficial in Neoadjuvant HER2+ Esophageal Adenocarcinoma? Are CPIs More Beneficial Than Paclitaxel in Gastric Adenocarcinoma?
FEATURING
Jennifer Eads
- 445 views
- July 14, 2020
- 3
Penn Medicine 2020 Updates in Oncology
2020 ASCO GI Cancer Update: Is There a Difference in Survival With FOLFIRINOX vs. Gemcitabine and Abraxane in Pancreatic Adenocarcinoma? Did FGFRi Pemigatinib Show PFS in Cholangiocarcinomas? Do IO Combinations Improve OS vs. Sorafenib in HCC?
FEATURING
Jennifer Eads
- 924 views
- July 14, 2020
- 4
Penn Medicine 2020 Updates in Oncology
2020 ASCO Penn Medicine Breaking News: Anticoagulation Regimens During COVID-19, HER2 Directed Therapies & Tolerability of BRAF Therapy in CRC
FEATURING
Joshua Bauml,
Pallavi Kumar,
Lynn Schuchter,
Jennifer Eads,
David Mintzer,
James Gerson,
Allyson Pishko
- 12 views
- July 16, 2020